Puma Biotechnology Inc [PBYI] stock is trading at $4.84, up 2.98%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PBYI shares have gain 9.50% over the last week, with a monthly amount drifted -5.10%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Puma Biotechnology Inc [NASDAQ: PBYI] stock has seen the most recent analyst activity on September 28, 2021, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $11 for it. On October 08, 2019, downgrade downgraded it’s rating to Sell and revised its price target to $8 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $24 on May 10, 2019. Cantor Fitzgerald downgraded its rating to a Neutral and reduced its price target to $20 on May 10, 2019. Leerink Partners started tracking with a Mkt Perform rating for this stock on January 17, 2019, and assigned it a price target of $21. In a note dated January 03, 2019, Guggenheim downgraded an Neutral rating on this stock.
Puma Biotechnology Inc [PBYI] stock has fluctuated between $2.32 and $6.07 over the past year. Puma Biotechnology Inc [NASDAQ: PBYI] shares were valued at $4.84 at the most recent close of the market.
Analyzing the PBYI fundamentals
Puma Biotechnology Inc [NASDAQ:PBYI] reported sales of 238.06M for the trailing twelve months, which represents a growth of 11.37%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.25, Equity is 0.53 and Total Capital is 0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.73 points at the first support level, and at 4.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.94, and for the 2nd resistance point, it is at 5.03.
Ratios To Look Out For
For context, Puma Biotechnology Inc’s Current Ratio is 1.73. Also, the Quick Ratio is 1.62, while the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 1.02, the price to book ratio is 2.31 and price to earnings (TTM) ratio is 4.94.
Transactions by insiders
Recent insider trading involved Cesano Alessandra, Director, that happened on Jul 18 ’25 when 27000.0 shares were sold. Director, Cesano Alessandra completed a deal on Jul 18 ’25 to buy 27000.0 shares. Meanwhile, Chief Financial Officer NOUGUES MAXIMO F sold 5587.0 shares on Jul 08 ’25.
